Days, after India announced “precaution dose” for healthcare, frontline workers and 60+ population with comorbidities, the government at the Centre is said to be in discussion with Pune-based Gennova Biopharmaceuticals to consider its mRNA vaccine for booster dose, said a report. Gennova’s Messenger RNA or mRNA vaccine is in the late-stage trial where it has already completed phase 2 studies and has progressed well in the third phase.Also Read – How COVID 'Precautionary Doses' Are Different From Booster Shots? Vaccine Panel Chief Explains
Related Listings
Leave a Reply
You must be logged in to post a comment.